With all due respect email them yourself, I don't need or expect them to confirm my views. Safe to assume they'll disagree with my sentiment though isn't it?
The pathology market littered with companies who think they are going to revolutionise the industry. Reality and their potential customer base often burst their bubble though. Same for research and innovation funding, the vast majority doesn't generate commercial success.
For me LBT's fortune lies with their imaging technology and expertise, not with the APAS itself. I think they will have greater success with their smart incubator and Woundvue..or just licensing their tech to other companies.
LBT Price at posting:
19.5¢ Sentiment: Hold Disclosure: Held
(20min delay)